nDatalyze Corp. (NDATF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
nDatalyze Corp. (NDATF) with AI Score 47/100 (Weak). nDatalyze Corp. is a healthcare company focused on applying machine learning to mental health. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026nDatalyze Corp. (NDATF) Healthcare & Pipeline Overview
nDatalyze Corp. develops and offers Sigmund, a machine-learning-based application targeting inefficiencies in the mental health system. By leveraging AI to predict mental health conditions, nDatalyze aims to address misdiagnosis and misprescription, positioning itself in the emerging digital health solutions market.
Investment Thesis
nDatalyze Corp. presents a speculative investment opportunity within the digital health space, predicated on the potential of its Sigmund platform. The company's focus on applying machine learning to mental health diagnostics addresses a critical need for improved accuracy and efficiency in the healthcare system. Key value drivers include the continued refinement of Sigmund's algorithms, expansion of its user base among healthcare providers, and potential partnerships with larger healthcare organizations. However, the company's negative ROE of -59.8% and negative Free Cash Flow of $-0.00B highlight the early stage and high-risk nature of this investment. Successful commercialization of Sigmund and achievement of profitability are crucial for realizing the company's potential. The company's beta of 0.59 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Focus on applying machine learning to improve mental health diagnostics.
- Sigmund platform aims to reduce misdiagnosis and misprescription.
- Headquartered in Calgary, Canada, indicating a North American market focus.
- Negative ROE of -59.8% reflects current unprofitability.
- Beta of 0.59 suggests lower volatility compared to the market.
Competitors & Peers
Strengths
- Proprietary machine learning technology.
- Focus on a specific problem in the mental health system.
- Potential for scalability through SaaS model.
- Experienced management team with expertise in AI and healthcare.
Weaknesses
- Limited operating history.
- Negative profitability and cash flow.
- Dependence on a single product (Sigmund).
- Small market capitalization.
Catalysts
- Upcoming: Publication of clinical studies demonstrating Sigmund's effectiveness.
- Upcoming: Regulatory approvals for Sigmund in key markets.
- Ongoing: Expansion of Sigmund's user base among healthcare providers.
- Ongoing: Development of new AI-powered features for Sigmund.
Risks
- Potential: Failure to achieve profitability and positive cash flow.
- Potential: Competition from established players in the EHR market.
- Potential: Regulatory hurdles and data privacy concerns.
- Ongoing: Dependence on a single product (Sigmund).
- Ongoing: Small market capitalization and limited liquidity.
Growth Opportunities
- Expansion of Sigmund's User Base: nDatalyze can grow by expanding the adoption of Sigmund among healthcare providers, including psychiatrists, psychologists, and general practitioners. This involves targeted marketing efforts, demonstrations of the platform's capabilities, and integration with existing EHR systems. The market for mental health software is projected to reach billions of dollars in the coming years, providing a significant opportunity for growth.
- Partnerships with Healthcare Organizations: Collaborating with hospitals, clinics, and mental health institutions can provide nDatalyze with access to a larger patient population and valuable data for refining Sigmund's algorithms. Strategic partnerships can also enhance the company's credibility and market reach. These partnerships could be structured as pilot programs, licensing agreements, or joint ventures, with timelines varying based on the specific agreement.
- Integration with Telehealth Platforms: Integrating Sigmund with telehealth platforms can extend its reach to patients in remote areas and improve access to mental healthcare. Telehealth is experiencing rapid growth, driven by increasing demand for convenient and affordable healthcare services. This integration could involve developing APIs or embedding Sigmund's functionality within existing telehealth applications, with potential integration timelines of 12-18 months.
- Development of New AI-Powered Features: nDatalyze can enhance Sigmund's capabilities by developing new AI-powered features, such as personalized treatment recommendations, early detection of mental health conditions, and predictive analytics for patient outcomes. These features can differentiate Sigmund from competing platforms and attract new users. Development timelines for new features could range from 6-12 months, depending on the complexity and data requirements.
- Geographic Expansion: nDatalyze can expand its operations beyond North America and target international markets with a growing need for mental health solutions. This involves adapting Sigmund to different languages and cultural contexts, as well as navigating regulatory requirements in each market. International expansion could be phased in over several years, starting with countries with similar healthcare systems and regulatory frameworks.
Opportunities
- Growing demand for digital mental health solutions.
- Potential for partnerships with larger healthcare organizations.
- Expansion into new geographic markets.
- Development of new AI-powered features.
Threats
- Competition from established players in the EHR market.
- Regulatory hurdles and data privacy concerns.
- Risk of technological obsolescence.
- Difficulty attracting and retaining qualified personnel.
Competitive Advantages
- Proprietary machine learning algorithms.
- Growing database of mental health records.
- First-mover advantage in applying AI to mental health diagnostics.
- Potential for network effects as more users adopt Sigmund.
About NDATF
nDatalyze Corp., formerly known as MedXtractor Corp., was founded in 2018 and is headquartered in Calgary, Canada. The company focuses on developing technology-driven solutions for the mental health sector. Its core product, Sigmund, is a machine-learning application designed to analyze patient data and predict potential mental health conditions. The goal is to improve diagnostic accuracy and reduce instances of misprescription within the mental health system. Sigmund is an online platform intended for use by healthcare professionals to aid in their assessment and treatment planning processes. nDatalyze aims to capitalize on the growing demand for digital health solutions and the increasing recognition of the importance of mental health. The company's strategic focus is on refining its machine learning algorithms and expanding the reach of the Sigmund platform within the healthcare industry. By leveraging data-driven insights, nDatalyze seeks to contribute to more effective and personalized mental healthcare.
What They Do
- Applies machine learning to a records database.
- Predicts probable mental health conditions.
- Offers Sigmund, a machine-learning-based online mental health application.
- Targets the mental health system to address misdiagnosis.
- Aims to reduce misprescription of medications.
- Provides technology-based solutions for mental healthcare.
Business Model
- Software as a Service (SaaS) model, licensing Sigmund to healthcare providers.
- Potential for subscription-based revenue.
- Data analytics services, providing insights to healthcare organizations.
- Partnerships and integrations with telehealth platforms.
Industry Context
The health information services industry is experiencing rapid growth, driven by increasing adoption of digital health solutions and the need for improved healthcare efficiency. Companies like nDatalyze are positioned to benefit from the growing demand for AI-powered diagnostic tools. The competitive landscape includes established players in the electronic health records (EHR) market, as well as emerging startups focused on specific applications of AI in healthcare. nDatalyze's success will depend on its ability to differentiate Sigmund and demonstrate its value proposition to healthcare providers.
Key Customers
- Psychiatrists
- Psychologists
- General Practitioners
- Hospitals and Clinics
- Mental Health Institutions
Financials
Chart & Info
nDatalyze Corp. (NDATF) stock price: Price data unavailable
Latest News
No recent news available for NDATF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NDATF.
Price Targets
Wall Street price target analysis for NDATF.
MoonshotScore
What does this score mean?
The MoonshotScore rates NDATF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Health Information ServicesNDATF OTC Market Information
NDATF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
nDatalyze Corp. Stock: Key Questions Answered
What does nDatalyze Corp. do?
nDatalyze Corp. is a technology company focused on the mental health sector. They have developed Sigmund, a machine-learning-based application designed to improve the accuracy of mental health diagnoses and prescriptions. By analyzing patient data, Sigmund aims to assist healthcare professionals in making more informed decisions, ultimately leading to better patient outcomes. The company's business model revolves around licensing Sigmund to healthcare providers and potentially offering data analytics services to healthcare organizations.
What do analysts say about NDATF stock?
As of 2026-03-17, there is no readily available analyst consensus on NDATF stock. Given the company's small market capitalization and early stage of development, it is not widely covered by major financial analysts. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's current lack of profitability. Investors should carefully consider the company's growth potential and risk factors before making any investment decisions.
What are the main risks for NDATF?
The main risks for nDatalyze Corp. include its limited operating history, negative profitability, and dependence on a single product (Sigmund). The company faces competition from established players in the EHR market and must navigate regulatory hurdles and data privacy concerns. Additionally, the company's small market capitalization and limited liquidity make it a high-risk investment. Successful commercialization of Sigmund and achievement of profitability are crucial for the company's long-term survival.
What are the key factors to evaluate for NDATF?
nDatalyze Corp. (NDATF) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary machine learning technology.. Primary risk to monitor: Potential: Failure to achieve profitability and positive cash flow.. This is not financial advice.
How frequently does NDATF data refresh on this page?
NDATF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NDATF's recent stock price performance?
Recent price movement in nDatalyze Corp. (NDATF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary machine learning technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NDATF overvalued or undervalued right now?
Determining whether nDatalyze Corp. (NDATF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NDATF?
Before investing in nDatalyze Corp. (NDATF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- AI analysis pending.
- OTC stocks are inherently risky.